Sustained release injectable composition containing naltrexone and method for preparing same
A sustained-release injectable composition with naltrexone microparticles and biodegradable polymers addresses adherence and side effects by providing controlled, continuous drug release for a month, enhancing treatment efficacy and compliance.
Patent Information
- Application Number
- JP2024528600
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-11-17
- Filing Date
- 2022-11-18
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing naltrexone treatments for alcohol dependence require daily oral administration, leading to challenges in adherence and potential liver damage, with long-acting injections causing initial drug bursts and side effects.
A sustained-release injectable composition containing naltrexone microparticles and biodegradable polymers, formulated to maintain effective blood levels for one month with controlled release, preventing initial bursts and ensuring uniform particle distribution.
The composition achieves continuous naltrexone release for a month without initial bursts, maintaining therapeutic effects while reducing side effects and improving patient compliance.
Smart Images

Figure 2024541381000001 
Figure 2024541381000002 
Figure 2024541381000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a sustained release injectable composition containing naltrexone and a method for preparing the same. [Background technology]
[0002] Alcohol dependence is defined as the persistent or periodic compulsive need to drink alcohol to avoid the discomforts of alcohol deprivation, resulting in various types of mental, physical and social disorders as a result of repeated and excessive alcohol intake.
[0003] According to the Korea Institute for Health and Social Affairs, 26.1% of Korean men, 10.5% of Korean women, and 20.9% of all adults were alcohol dependent in 2001. This means that one in five adults is alcohol dependent, which is causing increasing social problems and costs.
[0004] Naltrexone is an opioid receptor antagonist that has been approved by the U.S. Food and Drug Administration (FDA) since 1984 as a treatment for alcoholism.
[0005] At typical dosages (50 mg / person / day), naltrexone is known to bind to and block opioid receptors, thereby reducing the positive reinforcing effect of alcohol on increasing opioid secretion, and may increase the risk of liver cell damage when taken for a long period of time.
[0006] Due to concerns about side effects, it has been reported that naltrexone can be effectively used to treat alcoholism even when administered at reduced doses.
[0007] However, both the standard dosage and low-dose naltrexone medications require daily oral administration, and in the case of traditional naltrexone tablets taken orally every day, alcoholics have the problem of having to take medication and drink alcohol every day, making it difficult for them to break free from the temptation to drink alcohol.
[0008] To overcome these problems, naltrexone was developed as a long-acting injectable drug, with a dosage form that allows the effect to last for one month with a single administration. However, excessive amounts of the drug are administered to maintain the effective drug concentration in the blood, which can cause side effects due to the initial burst.
[0009] To solve the above problems, we have developed a single injection to increase the convenience of administration and a controlled release system to provide max There is a need to develop a sustained-release dosage form containing naltrexone that can maintain effective concentrations of the drug for one month while reducing the risk of developing naltrexone-induced hypercalcaemia. [Prior art documents] [Patent documents]
[0010] [Patent Document 1] KR10-2018-0129909A1 Summary of the Invention [Problem to be solved by the invention]
[0011] An object of the present invention is to provide a sustained release injectable composition containing naltrexone and a method for preparing the same.
[0012] Another object of the present invention is to provide a sustained release injectable composition containing naltrexone that can adjust the release rate of naltrexone at a target site, prevent an initial burst, and continuously release naltrexone for one month, thereby maintaining a blood concentration sufficient to exhibit the effects of naltrexone.
[0013] Another object of the present invention is to provide a method for producing microparticles that are homogeneous and have excellent quality while having a high encapsulation rate of naltrexone, a poorly soluble drug. [Means for solving the problem]
[0014] In order to achieve the above object, the present invention relates to a sustained release injectable composition containing naltrexone, comprising microparticles, the microparticles comprising naltrexone and a biodegradable polymer, and the value according to the following formula 1 may be 120 to 320: AUC inf / C max (Formula 1) Here, AUC inf (ng*hr / ml) is the area under the plasma concentration-time curve obtained by administering microparticles containing naltrexone as an injection to beagle dogs and measuring the blood concentration of naltrexone. C max (ng / ml) is the maximum blood concentration of naltrexone after administration of the naltrexone-containing microparticles as an injection to beagle dogs.
[0015] The microparticles may have a value according to the following formula 2 of 0.8 to 1.5:
[0016]
number
[0017] Where: D10 is the particle size that corresponds to 10% of the maximum value in the cumulative distribution of particles, D50 is the particle size that corresponds to 50% of the maximum value in the cumulative particle distribution, D90 is the particle size that corresponds to 90% of the maximum value in the cumulative particle distribution.
[0018] The composition may contain more than 240 mg but less than 310 mg of naltrexone.
[0019] The biodegradable polymer can be selected from the group consisting of polylactic acid, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazenes, polyiminocarbonates, polyphosphoesters, polyanhydrides, polyorthoesters, polycaprolactones, polyhydroxyvalerates, polyhydroxybutyrates, polyamino acids, and combinations thereof.
[0020] The microparticles may contain naltrexone and a biodegradable polymer in a weight ratio of 1:1 to 1:10.
[0021] When administered as an injection, the release rate of naltrexone is adjusted at the target site, allowing for sustained release of naltrexone for up to one month.
[0022] The injectable composition may include a suspending solvent.
[0023] A method for producing a sustained release injectable composition containing naltrexone according to another embodiment of the present invention includes the steps of: 1) dissolving naltrexone and a biodegradable polymer in a mixed solvent containing two or more organic solvents to produce an oil phase solution; 2) dissolving a surfactant in water to produce an aqueous phase solution; 3) producing microparticles containing naltrexone using the oil phase solution and the aqueous phase solution; and 4) mixing the microparticles with a suspension solvent, and the value according to the following formula 1 may be 120 to 320: AUC inf / C max (Formula 1) Here, AUC inf (ng*hr / ml) is the area under the plasma concentration-time curve obtained by administering microparticles containing naltrexone as an injection to beagle dogs and measuring the blood concentration of naltrexone. C max(ng / ml) is the maximum blood concentration of naltrexone after administration of the naltrexone-containing microparticles as an injection to beagle dogs.
[0024] The mixed solvent may include a first solvent and a co-solvent, and the first solvent may be dichloromethane.
[0025] The first solvent and the co-solvent are contained in a weight ratio of 1:0.5 to 1:10. Effect of the Invention
[0026] The present invention adjusts the release rate of naltrexone at the target site, preventing an initial burst and releasing naltrexone continuously for one month, thereby maintaining a sufficient blood concentration to exert the effects of naltrexone.
[0027] The present invention also relates to a production method for producing microparticles that are homogeneous and have excellent quality, and that have a high encapsulation rate of naltrexone, a poorly soluble drug. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0028] The present invention relates to a sustained release injectable composition comprising naltrexone, comprising microparticles, the microparticles comprising naltrexone and a biodegradable polymer, and the value according to the following formula 1 may be 120 to 320: AUC inf / C max (Formula 1) Here, AUC inf (ng*hr / ml) is the area under the plasma concentration-time curve obtained by administering microparticles containing naltrexone as an injection to beagle dogs and measuring the blood concentration of naltrexone. C max (ng / ml) is the maximum blood concentration of naltrexone after administration of the naltrexone-containing microparticles as an injection to beagle dogs. EXAMPLES
[0029] DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will now be described in detail with reference to the accompanying drawings, in which: FIG. 1 is a block diagram of a semiconductor memory device according to an embodiment of the present invention;
[0030] In the present invention, naltrexone is also known as N-Cyclopropyl-methylnoroxymorphone, N-Cyclopropylmethyl-14-hydroxydihydro-morphinone, 17-(Cyclopropylmethyl)-4,5α-epoxy-3,14-dihydroxymorphinan-6-one, EN-1639A, or UM-792.
[0031] The naltrexone may be a compound having the following formula:
[0032] [ka]
[0033] The naltrexone of the present invention may be a solvate, stereoisomer, prodrug, metabolite (e.g., 6β-naltrexol), derivative (e.g., naloxone), free base, or a combination thereof of naltrexone.
[0034] The stereoisomers refer to compounds that have the same molecular formula and the same connection method of the constituent atoms, but have different spatial arrangements between the atoms. The solvates refer to compounds solvated in an organic or inorganic solvent. The solvates are, for example, hydrates. The stereoisomers may be partial diastereomers or enantiomers. The prodrugs may be compounds that are converted into target compounds in vivo after administration of the compounds. The metabolites may be compounds that are produced by metabolic processes in vivo. The derivatives refer to compounds obtained by replacing a part of the structure of naltrexone with other atoms or atomic groups.
[0035] According to one embodiment of the present invention, a sustained release injectable composition containing naltrexone includes microparticles, and the microparticles include naltrexone and a biodegradable polymer, and may have a value of 120 to 320 according to the following formula 1: AUC inf / C max (Formula 1) Here, AUC inf (ng*hr / ml) is the area under the plasma concentration-time curve obtained by administering microparticles containing naltrexone as an injection to beagle dogs and measuring the blood concentration of naltrexone. C max (ng / ml) is the maximum blood concentration of naltrexone after administration of the naltrexone-containing microparticles as an injection to beagle dogs.
[0036] As a competitive antagonist with high affinity for the μ-receptor, naltrexone has greater potency than other full-potency drugs such as morphine and heroin.
[0037] Naltrexone, which has twice the antagonistic effect of naloxone, is used in several opioid treatments, such as Revia (oral tablet) or Vivitrol (intramuscular injection).
[0038] Clinical dose of Vivitrol (C max ) is 380 mg, which is three to four times the daily oral dose of naltrexone (i.e., 50 mg) for 28 days.
[0039] Also, various preparations of naltrexone hydrochloride containing combinations of naltrexone hydrochloride and other compounds are known, such as Contrave (oral tablet, 8 mg naltrexone hydrochloride and 90 mg bupropion hydrochloride), Embeda (oral capsule, 25:1 ratio of naltrexone hydrochloride and morphine sulfate), and Troxyca ER (oral capsule, 1.2 mg naltrexone hydrochloride and 10 mg oxycodone hydrochloride).
[0040] Such products are used to treat obesity and to relieve severe pain. As a non-selective opioid antagonist with no agonist activity, naltrexone is used with opioid full agonists (e.g., methadone) or partial agonists (e.g., buprenorphine) to reduce opioid abuse during treatment.
[0041] As described above, the clinical dose (C max ) is 380 mg, which is an excessive amount administered to maintain the therapeutic effect of naltrexone for one month. In other words, in the case of Vivitrol, if the dosage is administered below the clinical dose, there is a problem that the therapeutic effect of naltrexone cannot be maintained for one month.
[0042] As described below, in the case of Vivitrol, the AUC inf It can be confirmed that the (area under the blood concentration-time curve) value is large and an initial burst occurs after administration.
[0043] Therefore, it can be confirmed that the values according to the formula 1 are below the range of the present invention. This result indicates that the total amount of naltrexone released is large when the administered dose is large, but the majority of naltrexone is released at the beginning of administration.
[0044] Specifically, in the above formula 1, AUC inf means the degree of bioabsorption rate of naltrexone, and C max The value (ng / ml) relates to the maximum blood concentration of naltrexone. Therefore, the value obtained by the above formula 1 can confirm the relationship between the degree of bioabsorption of the total administered naltrexone and the maximum blood concentration.
[0045] In order for the absolute value of the above formula 1 to be large, C max A smaller value of indicates a larger value, or AUC inf The value of must be large. Therefore, C max A small value of AUC means that there is no excess release of naltrexone. inf A high value of α indicates excessive exposure to naltrexone, which may lead to problems with naltrexone side effects.
[0046] In contrast, the absolute value of Equation 1 is small because max The value of AUC increases or inf The value of C must be small. max A large value of AUC indicates excessive release of naltrexone, exceeding the appropriate blood concentration level for naltrexone to exert its effect. Side effects caused by excessive release are a problem, and infA small value means that the dose of naltrexone is too small to produce a sustained effect over a month, or that the bioabsorption rate is low.
[0047] Therefore, as in the present invention, the value according to formula 1 may be 120 to 320, 150 to 300, 170 to 280, 190 to 250, or 200 to 240. This means that the dose of naltrexone contained in the sustained release injectable composition within the above range is within an appropriate level, and the effect can be sustained for one month, and there is no excessive release of naltrexone.
[0048] The dose of naltrexone in the composition is more than 240 mg and less than 310 mg, and may be 245 to 305 mg. When the sustained release injectable composition contains naltrexone within the above range, the naltrexone can be continuously released for one month to exert its effect.
[0049] The microparticles may have a value according to the following formula 2 of 0.8 to 1.5:
[0050]
number
[0051] Where: D10 is the particle size that corresponds to 10% of the maximum value in the cumulative distribution of particles, D50 is the particle size that corresponds to 50% of the maximum value in the cumulative particle distribution, D90 is the particle size that corresponds to 90% of the maximum value in the cumulative particle distribution.
[0052] The D10, D50 and D90 refer to measurements of the diameter of a microparticle, and are taken to represent values corresponding to 10%, 50% and 90% of the maximum value on the cumulative distribution.
[0053] The above formula 2 defines the ratio of (D90-D50) and (D50-D10), and checks the degree of uniform particle distribution by checking the ratio of the difference between the particle size corresponding to 90% and the particle size corresponding to 50% of the maximum value in the cumulative distribution of particles within the average particle distribution, and the difference between the particle size corresponding to 50% and the particle size corresponding to 10%, and the closer the value is to 1, the more uniform the distribution width is.
[0054] Formula 2 of the present invention is for more clearly identifying the size distribution of the microparticles, and the value according to formula 2 may be 0.8 to 1.5, 0.8 to 1.2, 0.8 to 1.0, or 0.8 to 0.95. While satisfying the value according to formula 2, the average diameter (D50) of the microparticles may be more than 30 μm and less than 90 μm, or 33 μm to 80 μm. The value according to formula 2 falling within the range of the present invention means that the sizes of the microparticles are distributed close to the average diameter value.
[0055] This is because when microparticles of uniform size are injected into the body, the microparticles having a uniform size are biodegraded to a similar extent, and the biodegradation of the microparticles can have a naltrexone release effect.
[0056] That is, the release degree of naltrexone in the body of microparticles containing naltrexone is closely related to the particle size and specific surface area, and in order to increase the specific surface area, it is essential to use microparticles with a uniform diameter.By using microparticles with a very uniform particle size as described above, it is possible to prevent an initial burst when injected into the body, and to exhibit the release effect of naltrexone for a long period of time, and the effect of naltrexone can be exerted for one month.
[0057] In addition, when the average diameter (D50) of the microparticles is 90 μm or more, the syringe may become clogged when administered using a syringe. This is because the size of the microparticles is large, and the wettability is reduced, so that when mixed with a suspension solution, the microparticles disperse quickly for a while, but then precipitate quickly. This causes layer separation between the microparticles and the suspension solution, which makes it difficult for the microparticles to pass through the needle (21G) during injection.
[0058] To solve the above problems, it has been considered to use a different type of syringe (21G or larger), but this has the problem that the needle diameter is larger than that of commonly used syringes, which may induce fear and pain.
[0059] The biodegradable polymer is selected from the group consisting of polylactic acid, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazene, polyiminocarbonate, polyphosphoester, polyanhydride, polyorthoester, polycaprolactone, polyhydroxyvalerate, polyhydroxybutyrate, polyamino acid, and combinations thereof, preferably polylactide-co-glycolide (PLGA) or polylactide (PLA), but not limited to the above examples.
[0060] As an example, the molar ratio of glycolide to lactide in polylactide-co-glycolide may be about 60:40 to about 90:10, about 60:40 to about 85:15, about 60:40 to about 80:20, about 60:40 to about 75:25, about 65:35 to about 90:10, about 70:30 to about 90:10, about 75:25 to about 90:10, about 65:35 to about 85:15, or about 70:30 to about 80:20, but is not limited to the above examples. Preferably, the molar ratio of glycolide to lactide in polylactide-co-glycolide may be about 75:25.
[0061] The biodegradable polymer may include one or more polylactides and one or more polylactide-co-glycolides. In the present invention, the biodegradable polymer may include, for example, a combination of two polylactides, one polylactide and one polylactide-co-glycolide, two polylactide-co-glycolides, three polylactides, two polylactides and one polylactide-co-glycolide, one polylactide and two polylactide-co-glycolides, and in particular, one polylactide and one polylactide-co-glycolide, or two polylactide-co-glycolides, but is not limited thereto.
[0062] The biodegradable polymer can include two or more types of polylactide-co-glycolide.
[0063] The microparticles may contain naltrexone and a biodegradable polymer in a weight ratio of 1:1 to 1:10, 1:1 to 1:5, 1:1 to 1:4, or 1:2. Within the above range, the injectable composition may be prepared into a sustained release injection that continuously releases naltrexone for one month within the injectable dose range. That is, if the naltrexone is contained in an amount less than the above range compared to the biodegradable polymer, the amount of the injectable composition increases to match the total dose for administering naltrexone as an injection, which causes a problem of exceeding the amount of injection that can be administered to a person once. Also, if the naltrexone is contained in an amount exceeding the above range compared to the biodegradable polymer, it is not easy to prepare microparticles in which naltrexone is uniformly distributed.
[0064] As described above, the sustained release injectable composition containing naltrexone of the present invention can control the release rate of naltrexone at the target site when administered as an injection, thereby allowing the sustained release of naltrexone for one month, and can prevent an initial burst compared to conventional sustained release injectables.
[0065] Generally, naltrexone causes side effects such as feeling drunk or nauseous, and these side effects usually appear within the first 30 days after taking naltrexone.
[0066] In other words, this means that the problem of side effects caused by naltrexone is more likely to become a problem when there is excessive exposure to naltrexone in the early stages of administration.
[0067] In order to prevent such problems, in the present invention, the microparticles having a uniform particle size and in which naltrexone is evenly distributed are included in the sustained release injectable composition by the manufacturing method described below, thereby preventing the initial burst and enabling the continuous release of naltrexone for one month.
[0068] In other words, although the present invention releases naltrexone at a level above the effective blood concentration at which the effects of naltrexone can be exerted, it is possible to prevent excessive initial exposure that would cause side effects and to prevent administration of an excessive dose of naltrexone in order to maintain the efficacy for one month.
[0069] The injectable composition may contain a suspending medium, which contains an isotonic agent, a suspending agent and a solvent.
[0070] More specifically, the isotonicity agent can be selected from the group consisting of D-Mannitol, Maltitol, Sorbitol, Lactitol, Xylitol, Sodium chloride, and mixtures thereof, preferably D-Mannitol, but is not limited to the above examples.
[0071] The suspending agent may be sodium carboxymethylcellulose, polysorbate 80, starch, starch derivatives, polyhydric alcohols, chitosan, chitosan derivatives, cellulose, cellulose derivatives, collagen, gelatin, hyaluronic acid (HA), alginic acid, algin, pectin, carrageenan, chondroitin, chondroitin sulfate, dextran, dextran sulfate, polylysine, titin, fibrin, agarose, fluran, xanthan gum, etc. gum), and mixtures thereof, preferably sodium carboxymethylcellulose and polysorbate 80, but not limited to the above examples.
[0072] The solvent may be water for injection, and any solvent that can be used as water for injection may be used without limitation.
[0073] A method for preparing a sustained release injectable composition containing naltrexone according to one embodiment of the present invention includes the steps of: 1) dissolving naltrexone and a biodegradable polymer in a mixed solvent containing two or more organic solvents to prepare an oil phase solution; 2) dissolving a surfactant in water to prepare an aqueous phase solution; 3) preparing microparticles containing naltrexone using the oil phase solution and the aqueous phase solution; and 4) mixing the microparticles with a suspension solvent.
[0074] The mixed solvent for dissolving the naltrexone and the biodegradable polymer includes a first solvent and a co-solvent, and the first solvent may be dichloromethane.
[0075] Generally, to prepare microparticles using an organic solvent, a solvent in which the drug and biodegradable polymer are easily soluble is used, and a commonly used solvent is dichloromethane.
[0076] However, even when an organic solvent such as dichloromethane is used, some poorly soluble drugs have low solubility. In order to solve this problem, the present invention is characterized in that a co-solvent is added in addition to the first solvent to increase the solubility of naltrexone, and subsequently, the organic solvent can be easily removed.
[0077] The co-solvent has a density of 1.3 g / cm 3 or less, polarity index is 3 or less, boiling point is 50°C or less, water solubility is 2 20 ~8 20 g / 100g water. Specifically, the co-solvent may have a density of 1.3 g / cm 3 Less than 0.5-1.3g / cm 3 and 0.5 to 1.0 g / cm 3 and 0.6 to 0.9 g / cm 3 may be also possible.
[0078] The polarity is 3 or less, is 1-3, or may be 2-3.
[0079] The boiling point is 50°C or less, may be 30°C to 50°C, or may be 30°C to 40°C.
[0080] In addition, the water solubility is 2 20 ~8 20 g / 100g water, 3 20 ~8 20 g / 100g water, 5 20 ~8 20g / 100g water.
[0081] When a co-solvent that satisfies the above density conditions, polarity conditions, boiling point conditions, or water solubility is used in combination with the first solvent, it serves to increase the solubility of the poorly soluble drug naltrexone by assisting the first solvent. When a co-solvent is used to remove residual organic solvent from the prepared microparticles, the co-solvent is removed prior to the first solvent, dichloromethane, preventing the drug from escaping into the aqueous phase solution, and increasing the concentration or viscosity of the biodegradable polymer present in the oil phase solution, thereby strengthening the bond between naltrexone and the biodegradable polymer and increasing the encapsulation rate of naltrexone in the biodegradable polymer.
[0082] In addition, since the boiling point of the co-solvent is 50° C. or less, the properties of the biodegradable polymer do not change even when heated during the solvent removal process, and the release pattern of the microparticles does not change. In addition, since the co-solvent has a low density, even a small amount of the co-solvent can reduce the viscosity or density of the oil phase solution, thereby making it possible to produce uniform and high-quality microparticles.
[0083] Such a co-solvent may in particular be a volatile organic solvent or a volatile non-polar organic solvent.
[0084] The volatile organic solvent can be selected from the group consisting of acetone, acetonitrile, benzene, butyl alcohol carbon disulfide, carbon tetrachloride, chloroform, cyclohexane, 1,1-dichloroethane, dimethoxyethane, ethanol, diethyl ether, ethyl acetate, heptane, hexane, methanol, methyl acetate, methyl t-butyl ether, pentane, propyl alcohol, tetrahydrofuran, and combinations thereof.
[0085] Also, the volatile non-polar organic solvent can be selected from the group consisting of cyclohexane, pentane, hexane, heptane, carbon tetrachloride, carbon disulfide, benzene, diethyl ether, methyl t-butyl ether, tetrahydrofuran, ethyl acetate, methyl acetate, chloroform, and combinations thereof.
[0086] When the co-solvent is used as a mixed solvent with the first solvent, even if the co-solvent does not dissolve naltrexone or the biodegradable polymer well by itself, when it acts together with the first solvent, dichloromethane, it can increase the solubility of the poorly soluble drug or the biodegradable polymer and reduce the viscosity of the oil phase solution.
[0087] Also, as described above, the co-solvent may have the property of volatilizing or evaporating before dichloromethane. In general, the transfer of naltrexone to the aqueous solution occurs on the surface of the microparticles that are not completely dried, and as the organic solvent remaining inside the microparticles is removed, the internal viscosity increases and hardening occurs, which reduces the reactivity with the aqueous solution and reduces the probability of naltrexone transferring to the aqueous solution.
[0088] Therefore, when a cosolvent having the above-mentioned properties is used, the cosolvent is removed prior to the primary solvent, dichloromethane, preventing naltrexone from escaping into the aqueous phase solution, increasing the concentration or viscosity of the biodegradable polymer present in the oil phase solution, and strengthening the bond between naltrexone and the biodegradable polymer, thereby increasing the encapsulation rate of naltrexone within the biodegradable polymer.
[0089] In order to produce uniform and high-quality microparticles, the viscosity or density of the oil phase solution containing the microparticles, the biodegradable polymer, and the organic solvent is important. The co-solvent has a lower density than the primary solvent, so even if a small amount is used, it can reduce the density of the oil phase solution. When producing microparticles by a microfluidic method, the oil phase solution and the aqueous phase solution maintain laminar flow in the microchannel, making it possible to produce uniform and high-quality microparticles and to easily remove the residual organic solvent.
[0090] The co-solvent may be preferably diethyl ether or pentane, but is not limited to the above examples. Any co-solvent that satisfies the conditions of the co-solvent, increases the solubility of the poorly soluble drug naltrexone together with the first solvent, and has the property of volatilizing or evaporating before the first solvent can be used without limitation.
[0091] In step 1), the weight ratio of naltrexone to the mixed solvent may be, but is not limited to, about 1:7 to about 1:30, about 1:7 to about 1:29, about 1:7 to about 1:28, about 1:7 to about 1:27, about 1:7 to about 1:26, about 1:7 to about 1:25, about 1:7 to about 1:24, about 1:7 to about 1:23, about 1:7 to about 1:22, about 1:7 to about 1:21, about 1:7 to about 1:20, about 1:7 to about 1:19, about 1:7 to about 1:18, about 1:7 to about 1:17, about 1:7 to about 1:16, or about 1:7 to about 1:15.
[0092] In step 1), the weight ratio of naltrexone to the biodegradable polymer may be, but is not limited to, about 1:0.5 to about 1:10, about 1:0.5 to about 1:9, about 1:0.5 to about 1:8, about 1:0.5 to about 1:7, about 1:0.5 to about 1:6, or about 1:1 to about 1:5.
[0093] In step 1), the weight ratio of the co-solvent to the primary solvent may be, but is not limited to, about 1:0.5 to about 1:10, about 1:0.5 to about 1:9, about 1:0.5 to about 1:8, about 1:0.5 to about 1:7, or about 1:0.5 to about 1:6.
[0094] Preferably, the weight ratio of naltrexone to the mixed solvent is 1:15 to 1:20, and the weight ratio of the co-solvent to the first solvent may be 1:0.5 to 1:6, but is not limited to the above examples. Naltrexone can be well dissolved within the above range, and if the mixed solvent is contained below the above range, problems may occur in which naltrexone is recrystallized and precipitated, and the viscosity may become too high, which may cause difficulties in filtration and preparation. If an excessive amount of solvent is used, there is no major problem in preparation, but the absolute amount of organic solvent used may increase, naltrexone may be lost in the aqueous phase solution, and the remaining organic solvent may be difficult to remove.
[0095] The content of the biodegradable polymer in the organic solvent may be, but is not limited to, about 5 to about 50% by weight, about 5 to about 40% by weight, about 5 to about 30% by weight, about 5 to about 20% by weight, or about 5 to about 10% by weight based on the amount of the biodegradable polymer (e.g., polylactide-co-glycolide copolymer) used. The total amount of the organic solvent used can be changed depending on the viscosity of the biodegradable polymer and the amount of naltrexone used. If the amount of naltrexone is large or the viscosity of the biodegradable polymer is high, the amount of the organic solvent used can be increased to reduce the total concentration. However, when the biodegradable polymer is dissolved in the organic solvent within the above range, it is within a range in which the convenience of manufacturing microparticles is achieved and the removal of the residual organic solvent is also easy.
[0096] The biodegradable polymer is the same as that described above, so a detailed description of the related content will be omitted.
[0097] The aqueous phase solution may include water and a surfactant, and the surfactant may be any surfactant that can assist the oil phase solution in forming stable microparticles.
[0098] Specifically, the surfactant may be one or more selected from the group consisting of nonionic surfactants, anionic surfactants, cationic surfactants, and combinations thereof. For example, the surfactant may be any one or more selected from the group consisting of polyethylene glycol sorbitan monooleate, sorbitan oleate, sodium lauryl sulfate, polyvinyl alcohol (PVA), methylcellulose, polyvinylpyrrolidone, lecithin, gelatin, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene castor oil derivatives, sodium stearate, esteramines, linear diamines, fatty amines, and combinations thereof, but is not limited thereto.
[0099] The content of the surfactant contained in the aqueous phase solution may be, but is not limited to, 0.1 to 1.0% (w / v), 0.2 to 0.8% (w / v), 0.25 to 0.7% (w / v), 0.4 to 0.6% (w / v), 0.4 to 0.5% (w / v), 0.5 to 0.6% (w / v), 0.1 to 0.3% (w / v), 0.2 to 0.3% (w / v), or 0.25 to 0.3% (w / v). For example, the aqueous phase solution containing a surfactant may be, but is not limited to, a 0.5% (w / v) PVA solution.
[0100] The viscosity of the oil phase solution in step 1) is in a range where the viscosity of the fluid (unit: cP; centipoise) is such that the fluid maintains a laminar flow state in the microchannel. The viscosity of the fluid can be measured with a Brookfield Model LVT viscometer, and can be measured at 80 to 100 rpm using an LV01 or LV02 spindle. The viscosity of the oil phase solution is measured at 25°C. When the measurement is started with the viscometer, a certain value of viscosity is measured after the measurement solution is stabilized, and generally, the stabilization of the solution proceeds in about 1 minute.
[0101] The oil phase solution in step 1) may have a viscosity or density that allows it to maintain a laminar flow state together with the aqueous phase solution in step 2). Specifically, the oil phase solution may have a viscosity or density that allows the fluid in the microchannel to maintain a laminar flow state when the oil phase solution is injected into the aqueous phase solution flowing in the microchannel. For example, the oil phase solution may have a viscosity or density that allows the Reynolds number of the fluid flowing in the microchannel to satisfy 2,300 or less.
[0102] In the step 3), microparticles can be produced using an oil phase solution and an aqueous phase solution by an emulsion method, a porous membrane method, a spray drying method, or a microfluid method.
[0103] Specifically, the process for producing microparticles by the microfluidic method can include the steps of: a) injecting an oil phase solution into a linear microchannel; b) injecting an aqueous phase solution into the microchannel on both sides or one side; and c) collecting the microparticles.
[0104] The step a) is to inject an oil phase solution into a linear microchannel to allow it to flow, and the step b) is to inject an aqueous phase solution into a microchannel on one or both sides formed to form an intersection with the linear microchannel to allow it to flow, i.e., the oil phase solution flows along the linear microchannel, and the aqueous phase solution flows along a microchannel that forms an intersection with the linear microchannel on one or both sides based on the linear microchannel, and can meet the flow of the oil phase solution.
[0105] In addition, in order to make the flow of the aqueous phase solution that forms an intersection with the flow of the oil phase solution flow at a faster flow rate than the flow of the oil phase solution injected into a linear microchannel, it is possible to make the aqueous phase solution flow under higher pressure conditions.
[0106] As described above, by making the flow rates of the oil phase solution and the aqueous phase solution different and making the flow rate of the aqueous phase solution faster than that of the oil phase solution, the aqueous phase solution having a relatively faster flow rate compresses the oil phase solution at the point where the flows of the oil phase solution and the aqueous phase solution meet, and at this time, the biodegradable polymer and the poorly soluble drug naltrexone in the oil phase solution generate spherical microparticles due to the repulsive force between the oil phase solution and the aqueous phase solution, and the spherical microparticles can be formed in a form in which naltrexone is evenly distributed on the spherical biodegradable polymer.
[0107] The preparation of microparticles by the microfluid method is a method of forming microparticles of a certain size by introducing an oil phase solution in which naltrexone, an organic solvent, and a biodegradable polymer are dissolved together with an aqueous phase solution into a microchannel, and preparing microparticles in the aqueous phase solution. The microparticles thus formed are stabilized by the surfactant in the aqueous phase solution, and the organic solvent inside the particles is evaporated or volatilized according to the drying conditions, and the organic solvent inside the particles is removed to form microparticles.
[0108] The emulsion method is a method in which an oil phase solution in which naltrexone, an organic solvent, and a biodegradable polymer are dissolved is mixed with an aqueous phase solution containing a surfactant, and then external energy (ultrasonic waves, high-speed rotational force, etc.) is applied to the mixture to cause the oil phase solution to form microparticles in the aqueous phase solution. The microparticles formed by the emulsion method are formed by removing the organic solvent from the particles as the organic solvent inside the particles evaporates or volatilizes depending on the drying conditions.
[0109] The porous membrane method is a method for producing microparticles by flowing an oil phase solution (dispersed phase) in which naltrexone, an organic solvent, and a biodegradable polymer are dissolved onto one side of a porous membrane with micropores, and flowing an aqueous phase solution (continuous phase) containing a surfactant onto the opposite side of the porous membrane, thereby cutting the oil phase solution with the flow of the aqueous phase solution.
[0110] The spray drying method is a method for producing microparticles by spraying an oil phase solution in which naltrexone, an organic solvent, and a biodegradable polymer are dissolved, without using an aqueous phase solution, with a spray dryer while blowing in heated air. The oil phase solution is finely sprayed to form microparticles, and the organic solvent inside the particles is evaporated or volatilized by the heated air, removing the solvent, forming microparticles.
[0111] Specific examples of the emulsion method and spray drying method are described in, for example, the literature [Koerner, J. (2019). Harnessing Dendritic Cells for Poly (D, L-lactide-co-glycolide) Microspheres (PLGA MS) - Mediated Anti-tumor Therapy. Frontiers] and the literature [Wang, Y (2016). Manufacturing Techniques and Surface Engineering of Polymer Based Nanoparticles for Targeted Drug Delivery to Cancer. Nanomaterials 6 (2), 26], but are not limited thereto.
[0112] Another embodiment of the present invention provides microparticles containing naltrexone, which are prepared by the above-described method.
[0113] The loading rate of the microparticles for naltrexone may be about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%.
[0114] The microparticles are also called microspheres, and can refer to particles that can contain naltrexone as an active ingredient.
[0115] Experimental Example 1 Comparative study of encapsulation rate, residual organic solvent and dissolution of naltrexone microparticles by solvent (1) Preparation of Microparticles Containing Naltrexone Microparticles for use in the experiments were produced as described below, and the contents of the components used in producing the microparticles are summarized in Table 1.
[0116] [Example 1] 0.5 g of naltrexone in free base form and 1.0 g of DL-lactide / glycolide copolymer were mixed and dissolved in 10.0 g of dichloromethane and 2.3 g of diethyl ether. The mixed oil phase solution was applied to a microchannel, respectively, to fabricate microparticles at the intersection of the oil phase solution and the aqueous phase solution, which were collected above the aqueous phase solution (10° C.). The aqueous phase solution was a 0.5% (w / v) PVA solution (0.5% (v / v) PVA mixed in water).
[0117] The organic solvent was removed from the prepared microparticles by stirring at 10° C. for 1 hour, 30° C. for 1 hour, and 50° C. for 1 hour. The prepared microparticles were filtered and then freeze-dried to complete the preparation of dried microparticles.
[0118] [Example 2] The same preparation as in Example 1 was carried out, except that 8.0 g of dichloromethane and 2.0 g of diethyl ether were mixed.
[0119] [Comparative Example 1] The same preparation as in Example 3 was carried out, except that 8.0 g of dichloromethane was mixed without diethyl ether.
[0120] [Comparative Example 2] The same preparation as in Example 3 was carried out, except that 12.3 g of dichloromethane was mixed without diethyl ether.
[0121] [Table 1]
[0122] (2) Comparison of encapsulation rate, residual organic solvent, and precipitation depending on the use of co-solvent and the amount of organic solvent The solubility, encapsulation rate, and residual organic solvent were evaluated for the microparticles produced in Experimental Example 1(1). The presence or absence of dissolution was confirmed by visually checking for precipitation, and the encapsulation rate was measured using high-performance liquid chromatography (HPLC). The residual organic solvent was analyzed by gas chromatogram (GC). The results are shown in Table 2.
[0123] [Table 2]
[0124] When comparing Comparative Example 1 and Comparative Example 2, since naltrexone is poorly soluble in dichloromethane, if the amount of dichloromethane is insufficient, the naltrexone dissolved in the organic solvent during the preparation of the oil phase solution is precipitated by recrystallization, and as a result, microparticles cannot be prepared. When comparing Comparative Example 2 with Examples 1 and 2, it was confirmed that the encapsulation rate increased by about 6% when diethyl ether was used as a co-solvent compared to when dichloromethane was used alone, and the amount of residual organic solvent of dichloromethane was also reduced, and the amount of residual organic solvent of the entire mixture was also reduced.
[0125] According to the above results, the use of diethyl ether, which has a boiling point lower than that of dichloromethane, has the effect of increasing the encapsulation rate. This is because as diethyl ether evaporates at a lower temperature than dichloromethane, the concentration of naltrexone and biodegradable polymer in the microparticles increases, increasing the viscosity of the oil phase solution present in the microparticles, thereby maintaining the bond between naltrexone and the biodegradable polymer stronger.
[0126] Experimental Example 2 Comparative experiment on encapsulation rate, residual organic solvent, and dissolution of naltrexone microparticles depending on the mixing ratio of solvents (1) Preparation of Microparticles Containing Naltrexone Microparticles for use in the experiments were produced as described below, and the contents of the components used in producing the microparticles are summarized in Table 4.
[0127] [Example 3] 0.5g of naltrexone and 1.0g of DL-lactide / glycolide copolymer were mixed and dissolved in 6.0g of dichloromethane and 2.0g of diethyl ether. The mixed oil phase solution was applied to the microchannel respectively to prepare microparticles at the intersection of the oil phase solution and the aqueous phase solution, which were collected on the aqueous phase solution (10°C). The aqueous phase solution was a 0.5% (w / v) PVA solution. The prepared microparticles were stirred at 10°C for 1 hour, 30°C for 1 hour, and 50°C for 1 hour to remove the organic solvent. The prepared microparticles were obtained by sieving and then freeze-dried to complete the preparation of dried microparticles.
[0128] [Example 4] The microparticles were prepared as in Example 5, except that the organic solvent was removed by stirring at 10° C. for 1.5 hours, 30° C. for 1.5 hours, and 50° C. for 1.5 hours.
[0129] [Example 5] The same preparation as in Example 3 was carried out, except that 3.0 g of diethyl ether was added.
[0130] [Table 3]
[0131] (2) Comparison of encapsulation rate, residual organic solvent, and dissolution rate of naltrexone microparticles depending on the mixing ratio of solvents
[0132] [Table 4]
[0133] When comparing Example 3 and Example 4, it was confirmed that the encapsulation rate decreased as the organic solvent removal time was increased, and this result confirmed that there was no significant difference in the residual amount of organic solvent as the organic solvent removal time was increased.
[0134] When comparing Example 3 and Example 5, it was confirmed that the ratio of dichloromethane and diethyl ether used as the organic solvent affects the encapsulation rate. It can be confirmed that the encapsulation rate of naltrexone in the microparticles increases as the ratio of diethyl ether to dichloromethane increases.
[0135] Experimental Example 3 Particle size analysis To specifically ascertain the microparticle size, analysis was carried out using a Microtrac particle size analyzer.
[0136] The microparticles were prepared in a similar manner to Example 1 and assayed in triplicate.
[0137] The units of D10 to D90 are μm, and the experimental results are shown in Table 5 below.
[0138] [Table 5]
[0139] The microparticles prepared in Example 1 were confirmed to have D50 of 38.74 μm, 39.24 μm, and 38.46 μm, with standard deviations of 3.83, 3.61, and 3.89, indicating that the particle sizes were very uniform.
[0140] PSA particle size analysis was also performed on Vivitrol, revealing that the particle size distribution was D50 of 77.05 μm with a standard deviation of 27.99, indicating that the particle size was diverse.
[0141] In addition, it was confirmed that the calculation results of (D90-D50) / (D50-D10) in Table 5 showed uniform values without significant difference. In contrast, in the case of Vivitrol, it was confirmed that the value was 1.47, which is significantly different from the microparticles of the present invention.
[0142] Experimental Example 4 Pharmacokinetic Analysis The pharmacokinetic evaluation of the sustained release injectable composition of the present invention was confirmed.
[0143] The microparticles of Example 1 were added to 2.0 mL of a suspension solvent per vial, and then uniformly suspended to prepare a composition for subcutaneous injection.
[0144] The suspension solvent had the composition shown in Table 6 below.
[0145] [Table 6]
[0146] The injectable compositions were mixed with microparticles to give naltrexone contents of 200 mg, 245 mg, and 300 mg.
[0147] The injectable composition was administered to beagles by SC injection, and the blood concentration was measured every hour. As a control group, Vivitrol, which is currently on the market, was purchased and administered to beagles, and the blood concentration was measured in the same manner. The analysis results are shown in Table 7 below.
[0148] [Table 7]
[0149] According to the results of the experiment, in the case of Vivitrol, the blood concentration of naltrexone reached its maximum (C max In addition, when considering the dose of naltrexone contained in Vivitrol, it can be seen that there is a difference in the AUC measurement results.
[0150] In contrast, the microparticles of the present invention, which contain 245 mg of naltrexone, have a lower dose of naltrexone than Vivitrol, but they can be confirmed to release naltrexone continuously for one month and to exhibit blood naltrexone concentrations similar to those of Vivitrol even at 672 hours.
[0151] It can also be confirmed that the effect of naltrexone can be observed for one month even when 300 mg is administered. When 300 mg is administered, the C max Although it showed the maximum value, it was confirmed that the value was less than half, and it was confirmed that the initial burst was suppressed even when the administered dose was increased.
[0152] As a result, the sustained release injectable composition containing naltrexone of the present invention can maintain a sustained effect for one month while suppressing the initial burst of naltrexone compared to Vivitrol.
[0153] Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements made by those skilled in the art using the basic concept of the present invention defined in the following claims also fall within the scope of the present invention. [Industrial Applicability]
[0154] The present invention relates to a sustained release injectable composition containing naltrexone and a method for preparing the same.
[0155] This invention was supported by the following national research and development programs:
[0156] [Project unique number]1465031634 [Assignment number] HI20C0936 [Department name] Ministry of Health and Welfare [Name of issue management (specialized) organization] Korea Health Industry Promotion Agency [Research Project Name] Biohealth Investment Infrastructure Collaborative R&D [Research title] Development of long-acting injectables for the treatment of opioid and alcohol dependence using controlled and optimized manufacturing technology [Contribution rate] 1 / 1 [Name of project execution organization] Inventage Lab [Research period] 2022.01.01~2022.12.31
Claims
1. Contains microparticles, The microparticles comprise naltrexone and a biodegradable polymer; The value according to the following formula 1 is 120 to 320. Sustained release injectable compositions containing naltrexone: AUC inf / C max (Formula 1) Where: AUC inf (ng*hr / ml) is the area under the plasma concentration-time curve obtained by administering naltrexone-containing microparticles as an injection to a beagle dog and measuring the naltrexone blood concentration; C max (ng / ml) is the maximum blood concentration of naltrexone after administration of the naltrexone-containing microparticles as an injection to beagle dogs.
2. The microparticles have a value according to the following formula 2 of 0.8 to 1.5:
2. A sustained release injectable composition comprising naltrexone according to claim 1: [0010] Where: D10 is a particle size that corresponds to 10% of the maximum value in the cumulative distribution of particles, D50 is the particle size corresponding to 50% of the maximum value in the cumulative particle distribution, D90 is the particle size that corresponds to 90% of the maximum value in the cumulative distribution of particles.
3. The composition contains more than 240 mg but less than 310 mg of naltrexone.
2. A sustained release injectable composition comprising naltrexone according to claim 1.
4. The biodegradable polymer is selected from the group consisting of polylactic acid, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazenes, polyiminocarbonates, polyphosphoesters, polyanhydrides, polyorthoesters, polycaprolactones, polyhydroxyvalerates, polyhydroxybutyrates, polyamino acids, and combinations thereof; 2. A sustained release injectable composition comprising naltrexone according to claim 1.
5. The microparticles contain naltrexone and a biodegradable polymer in a weight ratio of 1:1 to 1:
10.
2. A sustained release injectable composition comprising naltrexone according to claim 1.
6. When administered as an injection, the release rate of naltrexone is adjusted at the target site, providing sustained release of naltrexone for one month.
2. A sustained release injectable composition comprising naltrexone according to claim 1.
7. The injectable composition comprises a suspension solvent; 2. A sustained release injectable composition comprising naltrexone according to claim 1.
8. 1) dissolving naltrexone and a biodegradable polymer in a mixed solvent containing two or more organic solvents to prepare an oil phase solution; 2) dissolving a surfactant in water to produce an aqueous phase solution; 3) producing microparticles containing naltrexone using the oil phase solution and the aqueous phase solution; 4) mixing the microparticles with a suspending solvent; The value according to the following formula 1 is 120 to 320. Method for preparing a sustained release injectable composition containing naltrexone: AUC inf / C max (Formula 1) Where: AUC inf(ng*hr / ml) is the area under the plasma concentration-time curve obtained by administering naltrexone-containing microparticles as an injection to a beagle dog and measuring the naltrexone blood concentration; C max (ng / ml) is the maximum blood concentration of naltrexone after administration of the naltrexone-containing microparticles as an injection to beagle dogs.
9. the mixed solvent comprises a first solvent and a co-solvent; The first solvent is dichloromethane; A method for preparing a sustained release injectable composition comprising naltrexone according to claim 8.
10. The first solvent and the co-solvent are included in a weight ratio of 1:0.5 to 1:10; A method for preparing a sustained release injectable composition comprising naltrexone according to claim 9.
Citation Information
Patent Citations
Injectable naltrexone microsphere composition and its use for reducing heroin and alcohol intake
JP2002541202A
Injectable long-acting naltrexone microparticle compositions
WO2020080806A1
PLGA microparticles, sustained release formulation thereof and method for manufacturing same
WO2020183718A1
Nalmefene, naltrexone or derivatives thereof for use in treating (NON)-alcoholic steatohepatitis or non-alcoholic fatty liver disease
KR1020180129909A
